Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11

  • Bioorg Med Chem Lett. 2011 Mar 15;21(6):1675-7. doi: 10.1016/j.bmcl.2011.01.098.
Huai-Qiang Ju  1 ,  Yang-Fei Xiang ,  Bao-Juan Xin ,  Ying Pei ,  Jia-Xin Lu ,  Qiao-Li Wang ,  Min Xia ,  Chui-Wen Qian ,  Zhe Ren ,  Sha-Yan Wang ,  Yi-Fei Wang ,  Guo-Wen Xing
Affiliations
  • 1. Guangzhou Jinan Biomedicine Research and Development Center, National Engineering Research Center of Genetic Medicine, Jinan University, Guangzhou, China.
PMID: 21334891 DOI: 10.1016/j.bmcl.2011.01.098
Abstract

In this study, a novel HSP90 Inhibitor BJ-B11, was synthesized and evaluated for in vitro Antiviral activity against several viruses. Possible anti-HSV-1 mechanisms were also investigated. BJ-B11 displayed no Antiviral activity against coxsackievirus B(3) (CVB(3)), human respiratory syncytial virus (RSV) and Influenza Virus (H1N1), but exhibited potent anti-HSV-1 and HSV-2 activity with EC(50) values of 0.42±0.18 μM and 0.60±0.21 μM, respectively. Additionally, the inhibitory effects of BJ-B11 against HSV-1 were likely to be introduced at early stage of Infection. Our results indicate that BJ-B11 with alternative mechanisms of action is potent as an anti-HSV clinical trial candidate.